Skip to main content
. Author manuscript; available in PMC: 2015 Jun 7.
Published in final edited form as: Cancer. 2010 Oct 1;116(19):4580–4589. doi: 10.1002/cncr.25319

Table 4. Response Outcomes With Modified Hyper-CVAD Versus Standard Hyper-CVAD.

Response Modified Hyper-CVAD, n = 68, % Hyper-CVAD, n = 208, % P
CR
 Overall 93 95 NS
 After course 1 78 77
CR with incomplete platelet recovery 1 0
Partial response 4 0 NS
Resistant disease 0 2 NS
Induction mortality 1 3 NS

Hyper-CVAD indicates fractionated cyclophosphamide, vincristine, doxoru-bicin, and dexamethasone; CR, complete response; NS, not significant.